Hello Folks! Welcome to Our Blog.

NASDAQ: ONTX was reduced by Zacks.com  from a “acquire” score to a “hold” rating in a research note released to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on uncovering as well as developing tiny molecule medication prospects to deal with cancer. The Firm‘s items under different phases of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research analysts likewise lately talked about the business. Noble Financial reissued a “acquire” ranking and released a $11.00 rate goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also set a “purchase” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving average price of $2.90 and also a two-hundred day relocating ordinary rate of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) incomes per share for the quarter, covering experts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and an adverse web margin of 8,294.27%. The firm had profits of $0.06 million during the quarter, contrasted to the consensus estimate of $0.06 million. Throughout the exact same quarter in the previous year, the firm uploaded ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will certainly post -1.18 EPS for the existing year.

A variety of hedge funds have just recently dealt shares of ONTX. GSA Funding Allies LLP purchased a new placement in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Capital Monitoring LP got a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also various other institutional capitalists have 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the recognition and also growth of oncology therapeutics. It focuses on uncovering and also developing tiny particle drug prospects to treat cancer. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more regarding research offerings from Zacks Investment Research, check out Zacks.com.

This instant information alert was created by narrative science modern technology as well as economic information from Market in order to offer viewers with the fastest and most precise reporting. This story was reviewed by Market’s editorial team prior to magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Prior to you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market monitors Wall Street’s top-rated and also finest executing research analysts and also the stocks they advise to their customers each day. Market has identified the 5 stocks that top experts are quietly murmuring to their customers to purchase now before the more comprehensive market catches on … and also Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics currently has a “Buy” score among experts, top-rated experts believe these five stocks are better buys.

Blue Ocean